DRTS
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Alpha Tau completed patient enrollment in its multicenter IMPACT pancreatic cancer pilot study of Alpha DaRTAug 31, 2026
- Alpha Tau successfully treated the first immunocompromised patient in the ADMIRE study for recurrent cutaneous squamous cell carcinomaJul 15, 2026
- Alpha Tau received FDA clearance to complete enrollment in the REGAIN glioblastoma trial and expand clinical sitesJun 11, 2026
- Alpha Tau reports strong interim results in recurrent glioblastoma trial with 100% local disease controlMay 11, 2026
- Alpha Tau successfully treated the first pancreatic cancer patient in Europe with Alpha DaRT in the French ACAPELLA clinical trialApr 24, 2026